ACIU: AC Immune SA Company Profile & Statistics

AC Immune SA Profile

About

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.

Info & Links

CEO

Andrea Pfeifer

Headquarters

EPFL INNOVATION PARK, BUILDING B
LAUSANNE, V8 1015, SWITZERLAND

Auditor

PricewaterhouseCoopers SA

Share holders

250

Employees

122

AC Immune SA Statistics

Valuation Measures

Market Capitalization²

294.63M

Enterprise Value

262.29M

Enterprise Value/EBITDA(ttm)

-3.25

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

68.01

Price to Book(mrq)

5.30

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-1977.71%

Profit Margin(ttm)

-2317.41%

Return on Equity(ttm)

-103.15%

Return on Invested Capital(ttm)

-107.71%

Return on Assets(ttm)

-39.10%

Income Statement

Revenue(ttm)

4.31M

Revenue Per Share(ttm)

0.04

Gross Profit(ttm)

4.31M

EBITDA(ttm)³

-80.65M

Net Income Available to Common(ttm)

-85.03M

Diluted EPS(ttm)

-0.84

Share Statistics

Beta (5Y Monthly)

1.64

52-Week Change

45.48%

S&P 500 52-Week Change

13.77%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

101.74M

Dividend Yield

0.00%

Float⁴

97.09M

% Held by Insiders

4.60%

% Held by Institutions

51.36%

Balance Sheet

Total Cash(mrq)

110.33M

Total Cash Per Share(mrq)

1.08

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

1.02%

Quick Ratio(mrq)

1.02%

Book Value Per Share(mrq)

0.53

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.83

Free Cash Flow(ytd)

-84.67M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

ACIU

AC Immune SA